Innovative Eyewear Inc current report, Q3 FY2024

Business Context and Reporting Period

Company: Innovative Eyewear, Inc. (Ticker: LUCY)
Filing Type: Form 8-K (Current Report)
Date of Report: September 22, 2024
Event Date: September 22, 2024 (Agreement); September 24, 2024 (Closing)
Context: The Company entered into inducement letter agreements with holders of existing warrants to facilitate a cash exercise of those warrants in exchange for the issuance of new warrants.

Key Financial Metrics

  • Gross Proceeds: Approximately $2.6 million from the exercise of existing warrants.
  • Use of Proceeds: Working capital and general corporate purposes.
  • Transaction Fees:
    • Placement Agent Cash Fee: 7.5% of gross proceeds.
    • Management Fee: 1.0% of gross proceeds.
    • Accountable Expenses: $25,000.
    • Clearing Expenses: $10,000.
  • Placement Agent Warrants: 19,737 shares (PA Warrants) issued to H.C. Wainwright & Co., LLC with an exercise price of $12.3438 per share.

Material Changes and Transaction Details

The Company executed a warrant exchange transaction involving the following components:

  • Existing Warrants Exercised: 263,160 shares at an adjusted exercise price of $9.875 per share (original price was $9.50).
  • New Warrants Issued (Inducement):
    • Series E Warrants: 263,160 shares; Exercise Price $9.50; Term 5 years; Immediately exercisable.
    • Series F Warrants: 526,320 shares; Exercise Price $9.50; Term 18 months; Immediately exercisable.
  • Registration Obligations: The Company agreed to file a resale registration statement within 30 days and seek effectiveness within 60 days (or 90 days if a full review is required).
  • Lock-up Provisions: The Company agreed not to issue new equity or file new registration statements for 10 days post-closing and is restricted from Variable Rate Transactions for one year.

Guidance, Outlook, and Risks

  • Management Commentary: The transaction was structured to induce cash exercise of existing warrants, providing immediate liquidity to the Company.
  • Risks and Contingencies:
    • The new warrants (Series E, Series F, and PA Warrants) were issued unregistered under Section 4(a)(2) and Rule 506 exemptions.
    • Future resale of shares underlying the new warrants is contingent upon the effectiveness of the Resale Registration Statement.
    • The Company faces dilution risk upon the exercise of the new warrants and PA Warrants.
  • Unusual Items: The filing does not disclose unusual items outside of the specific warrant inducement transaction.

Investor Verification Checklist

  • Verify the exact net proceeds after deducting the 8.5% total cash fees and fixed expenses.
  • Confirm the status of the Resale Registration Statement (Form S-1 or S-3) to ensure liquidity for the new warrant holders.
  • Review the total potential dilution from the 790,480 new warrant shares (Series E + Series F) plus 19,737 PA Warrant shares.
  • Check subsequent filings for the 10-day lock-up expiration regarding new equity issuances.